News

UroGen's bladder cancer treatment to be reviewed by FDA advisory committee
UroGen Pharma (NASDAQ:URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...
The Healthy @Reader's Digest2d
The TB Vaccine May Fight a Surprising Type of Cancer, Says New Research
Though the connection seems unusual, this news could change the lives of more than 700,000 Americans living with this disease ...
Orange County Business Journal2d
CG Oncology Jumps 25% on Positive Trial Results
CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...
CURE2d
A Personalized Approach to Bladder Preservation in Urologic Cancers
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...
WNCT on MSN1d
Congressman Murphy marks May as Bladder Cancer Awareness Month
Congressman Greg Murphy, M.D., is recognizing May as Bladder Cancer Awareness Month. “While most bladder cancers are caught ...
Fierce Healthcare2d
From Challenge to Change: Addressing Unmet Needs in Bladder Cancer Treatment
cretostimogene grenadenorepvec may be a much-needed advancement in the bladder cancer treatment paradigm that could help thousands of patients avoid surgery. Complete removal of the bladder is a ...
Clinical Trials Arena on MSN9d
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...
ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application
ImmunityBio is seeking an urgent meeting with U.S. health regulators after its bladder-cancer treatment application was rejected. The immunotherapy company said Monday that it received a ...
Business Wire2d
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unr…
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...
Frontiers5d
Bladder Cancer Awareness Month 2025: Current Developments and Insights in the Treatment of Bladder Cancer
May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...
ImmunityBio Slides Following FDA Refusal-to-File Letter
Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...